Designed proteins are anticipated to have groundbreaking impact on a range of issues from treating disease to tackling ...

Beyond the Scale” focuses on obesity as a chronic disease — urging empathy, early intervention, and evidence-based ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

"Beyond the Scale" launches across Singapore with a clear and urgent call to focus on obesity as not a failure of willpower, ...

India’s health regulator has approved Eli Lilly’s pre-filled pen version of Mounjaro, expanding its availability across six ...

Vietnam is experiencing a 38% increase in overweight and obesity rates, placing it among the Southeast Asian nations with the ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...